Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
Fuente:
arXiv
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Preprint |
| Publié: |
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866909974624468992 |
|---|---|
| author | Latent Labs Team Kenlay, Henry Pretorius, Daniella Crabbé, Jonathan Bridgland, Alex Schmon, Sebastian M. Hilmkil, Agrin Vuckovic, James Mathis, Simon Matteson, Tomas Bartke-Croughan, Rebecca Motmaen, Amir Rombach, Robin Vlachynská, Mária Nelson, Alexander W. R. Yuan, David Obika, Annette Kohl, Simon A. A. |
| author_facet | Latent Labs Team Kenlay, Henry Pretorius, Daniella Crabbé, Jonathan Bridgland, Alex Schmon, Sebastian M. Hilmkil, Agrin Vuckovic, James Mathis, Simon Matteson, Tomas Bartke-Croughan, Rebecca Motmaen, Amir Rombach, Robin Vlachynská, Mária Nelson, Alexander W. R. Yuan, David Obika, Annette Kohl, Simon A. A. |
| contents | Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and non-immunogenic from the start. Here we introduce Latent-X2, a frontier generative model that achieves this goal through zero-shot design of antibodies with strong binding affinities, drug-like properties, and, for the first time for any de novo generated antibody, confirmed low immunogenicity in human donor panels. Latent-X2 is an all-atom model conditioned on target structure, epitope specification, and optional antibody framework, jointly generating sequences and structures while modelling the bound complex. Testing only 4 to 24 designs per target in each modality, we successfully generated VHH and scFv antibodies against 9 of 18 evaluated targets, achieving a 50% target-level success rate with picomolar to nanomolar binding affinities. Designed molecules exhibit developability profiles that match or exceed those of approved antibody therapeutics, including expression yield, aggregation propensity, polyreactivity, hydrophobicity, and thermal stability, without optimization, filtering, or selection. In the first immunogenicity assessment of any AI-generated antibody, representative de novo VHH binders targeting TNFL9 exhibit both potent target engagement and low immunogenicity across T-cell proliferation and cytokine release assays. The model generalizes beyond antibodies: against K-Ras, long considered undruggable, we generated macrocyclic peptide binders competitive with trillion-scale mRNA display screens. These properties emerge directly from the model, demonstrating the therapeutic viability of zero-shot molecular design, now available without AI infrastructure or coding expertise at https://platform.latentlabs.com. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2512_20263 |
| institution | arXiv |
| publishDate | 2025 |
| record_format | arxiv |
| spellingShingle | Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2 Latent Labs Team Kenlay, Henry Pretorius, Daniella Crabbé, Jonathan Bridgland, Alex Schmon, Sebastian M. Hilmkil, Agrin Vuckovic, James Mathis, Simon Matteson, Tomas Bartke-Croughan, Rebecca Motmaen, Amir Rombach, Robin Vlachynská, Mária Nelson, Alexander W. R. Yuan, David Obika, Annette Kohl, Simon A. A. Biomolecules Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and non-immunogenic from the start. Here we introduce Latent-X2, a frontier generative model that achieves this goal through zero-shot design of antibodies with strong binding affinities, drug-like properties, and, for the first time for any de novo generated antibody, confirmed low immunogenicity in human donor panels. Latent-X2 is an all-atom model conditioned on target structure, epitope specification, and optional antibody framework, jointly generating sequences and structures while modelling the bound complex. Testing only 4 to 24 designs per target in each modality, we successfully generated VHH and scFv antibodies against 9 of 18 evaluated targets, achieving a 50% target-level success rate with picomolar to nanomolar binding affinities. Designed molecules exhibit developability profiles that match or exceed those of approved antibody therapeutics, including expression yield, aggregation propensity, polyreactivity, hydrophobicity, and thermal stability, without optimization, filtering, or selection. In the first immunogenicity assessment of any AI-generated antibody, representative de novo VHH binders targeting TNFL9 exhibit both potent target engagement and low immunogenicity across T-cell proliferation and cytokine release assays. The model generalizes beyond antibodies: against K-Ras, long considered undruggable, we generated macrocyclic peptide binders competitive with trillion-scale mRNA display screens. These properties emerge directly from the model, demonstrating the therapeutic viability of zero-shot molecular design, now available without AI infrastructure or coding expertise at https://platform.latentlabs.com. |
| title | Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2 |
| topic | Biomolecules |
| url | https://arxiv.org/abs/2512.20263 |